Statin responder analysis for precision prevention of Alzheimer’s Disease

Previously we identified reduced risk of Alzheimer’s Disease (AD) in statin users (Torrandell‐Haro et al. 2020). Identifying the subgroup of responders is an important step towards a precision statin therapy approach. This study aimed to investigate the effect of statin therapy on the incidence of Alzheimer’s Disease (AD) and other age‐related neurodegenerative diseases (NDD) by therapy, sex, and age group. Moreover, it sought to identify and describe responder vs non‐responder phenotypes to statin therapy based on demographic characteristics, comorbidity burden, and drug exposure.